{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T02:32:32Z","timestamp":1686882752790},"reference-count":24,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2013,8,6]],"date-time":"2013-08-06T00:00:00Z","timestamp":1375747200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"DOI":"10.1007\/s11845-013-0995-x","type":"journal-article","created":{"date-parts":[[2013,8,8]],"date-time":"2013-08-08T17:54:43Z","timestamp":1375984483000},"source":"Crossref","is-referenced-by-count":3,"title":["Osteogenesis imperfecta in adults: phenotypic characteristics and response to treatment in an Irish cohort"],"prefix":"10.1007","author":[{"given":"E. S.","family":"O\u2019Sullivan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"van der Kamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Kilbane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"McKenna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,8,6]]},"reference":[{"key":"995_CR1","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jmg.16.2.101","volume":"16","author":"DO Sillence","year":"1979","unstructured":"Sillence DO, Senn A, Danks DM (1979) Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 16:101\u2013116","journal-title":"J Med Genet"},{"key":"995_CR2","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrendo.2011.81","volume":"7","author":"A Forlino","year":"2011","unstructured":"Forlino A, Cabral WA, Barnes AM, Marini JC (2011) New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol 7:540\u2013557","journal-title":"Nat Rev Endocrinol"},{"key":"995_CR3","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.ajhg.2012.06.011","volume":"91","author":"O Semler","year":"2012","unstructured":"Semler O, Garbes L, Keupp K et al (2012) A mutation in the 5\u2032-UTR of IFITM5 creates an in-frame start codon and causes autosomal-dominant osteogenesis imperfecta type V with hyperplastic callus. Am J Hum Genet 91:349\u2013357","journal-title":"Am J Hum Genet"},{"key":"995_CR4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.ajhg.2012.06.005","volume":"91","author":"TJ Cho","year":"2012","unstructured":"Cho TJ, Lee KE, Lee SK et al (2012) A single recurrent mutation in the 5\u2032-UTR of IFITM5 causes osteogenesis imperfecta type V. Am J Hum Genet 91:343\u2013348","journal-title":"Am J Hum Genet"},{"key":"995_CR5","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/humu.20799","volume":"29","author":"D Baldridge","year":"2008","unstructured":"Baldridge D, Schwarze U, Morello R et al (2008) CRTAP and LEPRE1 mutations in recessive osteogenesis imperfecta. Hum Mutat 29:1435\u20131442","journal-title":"Hum Mutat"},{"key":"995_CR6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S0140-6736(04)16051-0","volume":"363","author":"F Rauch","year":"2004","unstructured":"Rauch F, Glorieux FH (2004) Osteogenesis imperfecta. Lancet 363:1377\u20131385","journal-title":"Lancet"},{"key":"995_CR7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmg.2009.10.007","volume":"53","author":"FS Dijk Van","year":"2010","unstructured":"Van Dijk FS, Pals G, Van Rijn RR, Nikkels PG, Cobben JM (2010) Classification of osteogenesis imperfecta revisited. Eur J Med Genet 53:1\u20135","journal-title":"Eur J Med Genet"},{"key":"995_CR8","first-page":"943","volume":"155A","author":"ML Warman","year":"2010","unstructured":"Warman ML, Cormier-Daire V, Hall C et al (2010) Nosology and classification of genetic skeletal disorders: 2010 revision. Am J Med Genet A 155A:943\u2013968","journal-title":"Am J Med Genet A"},{"key":"995_CR9","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF00350961","volume":"16","author":"JP Devogelaer","year":"1987","unstructured":"Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C (1987) Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta. Skeletal Radiol 16:360\u2013363","journal-title":"Skeletal Radiol"},{"key":"995_CR10","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","volume":"24","author":"F Rauch","year":"2009","unstructured":"Rauch F, Munns CF, Land C, Cheung M, Glorieux FH (2009) Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Bone Miner Res 24:1282\u20131289","journal-title":"J Bone Miner Res"},{"key":"995_CR11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1210\/jc.2010-0636","volume":"96","author":"LM Ward","year":"2011","unstructured":"Ward LM, Rauch F, Whyte MP et al (2011) Alendronate for the treatment of pediatric osteogenesis imperfecta: a randomized placebo-controlled study. J Clin Endocrinol Metab 96:355\u2013364","journal-title":"J Clin Endocrinol Metab"},{"key":"995_CR12","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1359\/jbmr.090712","volume":"25","author":"N Bishop","year":"2010","unstructured":"Bishop N, Harrison R, Ahmed F et al (2010) A randomized, controlled dose-ranging study of risedronate in children with moderate and severe osteogenesis imperfecta. J Bone Miner Res 25:32\u201340","journal-title":"J Bone Miner Res"},{"key":"995_CR13","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1359\/jbmr.2003.18.1.126","volume":"18","author":"S Adami","year":"2003","unstructured":"Adami S, Gatti D, Colapietro F et al (2003) Intravenous neridronate in adults with osteogenesis imperfecta. J Bone Miner Res 18:126\u2013130","journal-title":"J Bone Miner Res"},{"key":"995_CR14","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1359\/JBMR.051015","volume":"21","author":"G Chevrel","year":"2006","unstructured":"Chevrel G, Schott AM, Fontanges E et al (2006) Effects of oral alendronate on BMD in adult patients with osteogenesis imperfecta: a 3-year randomized placebo-controlled trial. J Bone Miner Res 21:300\u2013306","journal-title":"J Bone Miner Res"},{"key":"995_CR15","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00198-011-1658-2","volume":"23","author":"LA Bradbury","year":"2012","unstructured":"Bradbury LA, Barlow S, Geoghegan F et al (2012) Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int 23:285\u2013294","journal-title":"Osteoporos Int"},{"key":"995_CR16","first-page":"101","volume":"101","author":"MJ McKenna","year":"2008","unstructured":"McKenna MJ, van der Kamp S, Au-Yeong M, FitzGerald O (2008) Improving standards of DXA. Ir Med J 101:101\u2013102","journal-title":"Ir Med J"},{"key":"995_CR17","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.bone.2006.11.020","volume":"40","author":"F Rauch","year":"2007","unstructured":"Rauch F, Cornibert S, Cheung M, Glorieux FH (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821\u2013827","journal-title":"Bone"},{"key":"995_CR18","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1359\/JBMR.051207","volume":"21","author":"C Land","year":"2006","unstructured":"Land C, Rauch F, Glorieux FH (2006) Cyclical intravenous pamidronate treatment affects metaphyseal modeling in growing patients with osteogenesis imperfecta. J Bone Miner Res 21:374\u2013379","journal-title":"J Bone Miner Res"},{"key":"995_CR19","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1359\/JBMR.040814","volume":"19","author":"CF Munns","year":"2004","unstructured":"Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH (2004) Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate. J Bone Miner Res 19:1779\u20131786","journal-title":"J Bone Miner Res"},{"issue":"475\u201383","key":"995_CR20","first-page":"e3","volume":"121","author":"LM Hess","year":"2008","unstructured":"Hess LM, Jeter JM, Benham-Hutchins M, Alberts DS (2008) Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 121(475\u201383):e3","journal-title":"Am J Med"},{"key":"995_CR21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00774-011-0331-3","volume":"30","author":"E Maines","year":"2012","unstructured":"Maines E, Monti E, Doro F, Morandi G, Cavarzere P, Antoniazzi F (2012) Children and adolescents treated with neridronate for osteogenesis imperfecta show no evidence of any osteonecrosis of the jaw. J Bone Miner Metab 30:434\u2013438","journal-title":"J Bone Miner Metab"},{"key":"995_CR22","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1002\/jbmr.253","volume":"25","author":"E Shane","year":"2010","unstructured":"Shane E, Burr D, Ebeling PR et al (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267\u20132294","journal-title":"J Bone Miner Res"},{"key":"995_CR23","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1002\/jbmr.1768","volume":"27","author":"EB Andrews","year":"2012","unstructured":"Andrews EB, Gilsenan AW, Midkiff K et al (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7\u00a0years. J Bone Miner Res 27:2429\u20132437","journal-title":"J Bone Miner Res"},{"key":"995_CR24","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434\u20131441","journal-title":"N Engl J Med"}],"container-title":["Irish Journal of Medical Science"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-013-0995-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11845-013-0995-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-013-0995-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:14:51Z","timestamp":1559430891000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11845-013-0995-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,6]]},"references-count":24,"alternative-id":["995"],"URL":"https:\/\/doi.org\/10.1007\/s11845-013-0995-x","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"value":"0021-1265","type":"print"},{"value":"1863-4362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,6]]}}}